| pubmed-article:18285545 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C0205653 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C0332161 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C1521725 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C2828008 | lld:lifeskim |
| pubmed-article:18285545 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:18285545 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:18285545 | pubmed:dateCreated | 2008-4-28 | lld:pubmed |
| pubmed-article:18285545 | pubmed:abstractText | The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification. These aims were pursued through a stratification strategy using white blood cell count, age, immunophenotype, treatment response, and unfavorable genetic aberrations providing an excellent discrimination of risk groups. Estimated 6-year event-free survival (6y-pEFS) for all 2169 patients was 79.6% (+/- 0.9%). The large standard-risk (SR) group (35% of patients) achieved an excellent 6y-EFS of 89.5% (+/- 1.1%) despite significant reduction of anthracyclines. In the medium-risk (MR) group (53% of patients), 6y-pEFS was 79.7% (+/- 1.2%); no improvement was accomplished by the randomized use of additional intermediate-dose cytarabine after consolidation. Omission of preventive cranial irradiation in non-T-ALL MR patients was possible without significant reduction of EFS, although the incidence of central nervous system relapses increased. In the high-risk (HR) group (12% of patients), intensification of consolidation/reinduction treatment led to considerable improvement over the previous ALL-BFM trials yielding a 6y-pEFS of 49.2% (+/- 3.2%). Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients. | lld:pubmed |
| pubmed-article:18285545 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18285545 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18285545 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18285545 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:18285545 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18285545 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18285545 | pubmed:month | May | lld:pubmed |
| pubmed-article:18285545 | pubmed:issn | 1528-0020 | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:MannGeorgG | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:NiethammerDie... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:UrbanChristia... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:LudwigWolf-Di... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:WelteKarlK | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:BodeUdoU | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:BoosJoachimJ | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:BeierRitaR | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:SchrappeMarti... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:HenzeGünterG | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:GadnerHelmutH | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:HarbottJochen... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:NiemeyerCharl... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:KlingebielTho... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:ZintlFelixF | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:ReiterAlfredA | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:RiehmHansjörg... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:StanullaMarti... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:ZimmermannMar... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:NiggliFelixF | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:LöningLutzL | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:RateiRichardR | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:FeldgesAndrea... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:DördelmannMic... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:BeckJörn-Dirk... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:MörickeAnjaA | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:WehingerHelmu... | lld:pubmed |
| pubmed-article:18285545 | pubmed:author | pubmed-author:German-Austri... | lld:pubmed |
| pubmed-article:18285545 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18285545 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:18285545 | pubmed:volume | 111 | lld:pubmed |
| pubmed-article:18285545 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18285545 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18285545 | pubmed:pagination | 4477-89 | lld:pubmed |
| pubmed-article:18285545 | pubmed:dateRevised | 2009-6-2 | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:meshHeading | pubmed-meshheading:18285545... | lld:pubmed |
| pubmed-article:18285545 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18285545 | pubmed:articleTitle | Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. | lld:pubmed |
| pubmed-article:18285545 | pubmed:affiliation | Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. | lld:pubmed |
| pubmed-article:18285545 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18285545 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18285545 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18285545 | lld:pubmed |
